Bloom Science to Present at 24th Annual Biotech in Europe Forum

SAN DIEGO, Calif., September 24, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will be presenting at the 24th Annual Biotech in Europe Forum being held September 25-26, 2024 in Basel Switzerland.

Details are as follows:

• 24^rd Annual Biotech in Europe Forum
  Details: Dr. Reyes will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference dates: September 25-26, 2024
  Presentation Timing: 14:05 CEST on September 25, 2024

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.

Christopher Reyes, Founder and CEO of Bloom Science, joins a panel of experts to explore the Science of the Gut-Brain Axis 

SAN DIEGO, Calif., August 5, 2024 —Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that CEO Christopher Reyes will join a panel of entrepreneurs and researchers as they discuss the complexities of the gut microbiome and its profound impact on mental health and overall well-being.

Gut Feelings: Exploring the Gut-Brain Connection Lecture
Tue, Aug 6; 6:30P – 8:00P
The Battery SF

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.

Bloom Science to Participate at Upcoming Patient Advocacy Conferences

SAN DIEGO, Calif., June 20, 2024 — Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that the company will participate in two upcoming patient advocacy conferences.

2024 Dravet Syndrome Foundation Conference in Minneapolis
Date: June 20-22, 2024
Location: Minneapolis

ALS Nexus 2024
Date: July 14 – 17, 2024
Location: Dallas

Poster Presentation: Development of BL-001 for the Treatment of ALS through Multiple Gut-Brain Mediated Pathways. PResenter: Christopher Reyes, PhD

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.

Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome

SAN DIEGO, Calif., March 12, 2024 —The gut microbiome plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. In today’s IamBIO episode, Bloom’s CEO Chris Reyes joins other experts who tell us where the science is—how much we know, and how much we don’t.

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.

Bloom Science to Present at the Biocom Global Partnering & Investor Conference

SAN DIEGO, Calif., February 20, 2024 — Bloom Science, Inc., today announced that Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science, will be presenting at the Biocom Global Partnering & Investor Conference being held February 27-29, 2024 at the Lodge at Torrey Pines in La Jolla, CA.

Biocom Global Partnering & Investor Conference
Date: Wednesday, February 28, 2024
Time: 12:15 p.m. PT

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders. For more information, visit: https://bloomscience.com/